Agilent Technologies Inc Stock Price, News & Analysis

Crawford & Company (NYSE: CRD-A and CRD-B) has announced its quarterly dividend declaration following its regular board meeting on May 7, 2025. The company will distribute a dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on June 6, 2025, to shareholders who are on record as of the market close on May 23, 2025.

TORM plc (NASDAQ: TRMD) has announced a capital increase through the issuance of 18,769 A-shares, with a nominal value of USD 187.69, following the exercise of Restricted Share Units as part of its incentive program. The new shares were subscribed for in cash at DKK 0.08 per A-share.

The new ordinary shares will carry standard rights, including dividend eligibility from the issuance date, and are expected to be listed on Nasdaq Copenhagen. Following this capital increase, TORM's total share capital stands at USD 982,829.85, consisting of 98,282,983 A-shares, one B-share, and one C-share, each with a USD 0.01 par value. The A-shares carry 98,282,983 votes, while the B and C shares maintain specific voting rights.

Agilent Technologies (NYSE: A) has announced its participation at the AACR Annual Meeting 2025 in Chicago, showcasing innovative cancer research solutions. The company unveiled three new Avida DNA Cancer Panels for ultra-sensitive detection of cancer genomic alterations from liquid biopsies, featuring a streamlined 5-hour workflow.

Key highlights include partnerships with Tagomics for their Interlace Multiomics assay integration with Agilent's SureSelect Cancer CGP assay, and collaboration with Roswell Park Cancer Center for the SureSelect Cancer Pan Heme Assay. Additionally, Agilent announced a strategic partnership with Abcam for IHC Companion Diagnostics development using Abcam's portfolio of over 10,000 recombinant monoclonal antibodies.

Agilent Technologies (NYSE: A) has received European IVDR certification for its PD-L1 IHC 22C3 pharmDx assay as a Companion Diagnostic (CDx) for gastric or gastroesophageal junction (GEJ) adenocarcinoma patients. The certification aids in identifying patients eligible for KEYTRUDA® therapy.

The assay is now IVDR certified for seven cancer indications, including non-small cell lung cancer, urothelial carcinoma, esophageal cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and cervical cancer. It remains the only IVDR-certified CDx for gastric and GEJ adenocarcinoma patients seeking KEYTRUDA treatment.

This expansion is particularly significant given that gastric cancer affected over 130,000 Europeans in 2022, with a 5-year survival rate of 26% in Europe. The assay works exclusively with Agilent's Autostainer Link 48 advanced staining solution.

Agilent Technologies (NYSE: A) has scheduled the release of its second-quarter fiscal year 2025 financial results after market close on Wednesday, May 28. The company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website, where a recording will remain available for 90 days.

Agilent Technologies (NYSE: A) has announced its contribution to the FDA approval of AUCATZYL®, a CAR T therapy developed by Autolus Therapeutics. The company's xCELLigence Real-Time Cell Analysis (RTCA) technology played a important role in developing and validating the therapy's potency assay.

The xCELLigence RTCA platform provides continuous, real-time monitoring of cell behavior without labels or dyes, using electrical impedance to measure cell numbers, viability, and morphology. This technology offers advantages over traditional endpoint assays by enabling more accurate and timely decision-making in drug development.

Agilent and Autolus will present their findings at the 2025 Hybrid US Bioassay Conference in Tucson, Arizona, discussing lessons learned in CAR T Cell Product Potency Measurement.

Agilent Technologies (NYSE: A) will showcase its digital pathology solutions at the USCAP Conference in Boston, March 22-27, 2025. The company has developed an end-to-end digital pathology workflow in collaboration with Hamamatsu, PathAI, Proscia, and Visiopharm, integrating AI-driven precision pathology software with automated staining solutions.

The showcase will feature live demonstrations of scanning, image management, and AI-driven image analysis capabilities. Key products to be displayed include the Magnis NGS Prep System and NovoCyte Opteon Spectral Flow Cytometer.

Two symposiums are scheduled for March 24: a Digital Pathology Symposium on innovations and insights (12:00-1:00 PM ET) and a Medical Affairs Symposium focusing on PD-L1 Heterogeneity (5:30-7:00 PM ET).

Agilent Technologies (NYSE: A) has announced its participation in the USCAP Conference from March 22-27, 2025, in Boston, where it will showcase advanced digital pathology solutions. The company has developed an end-to-end digital pathology workflow in collaboration with Hamamatsu, PathAI, Proscia, and Visiopharm.

The integrated solution combines AI-driven precision pathology software with automated staining solutions, covering processes from tissue sample scanning to image analysis and data management. Key products to be showcased include the Magnis NGS Prep System and NovoCyte Opteon Spectral Flow Cytometer.

Two significant symposiums are scheduled for March 24: a Digital Pathology Symposium (12:00-1:00 PM ET) featuring experts from various institutions, and a Medical Affairs Symposium on PD-L1 Heterogeneity (5:30-7:00 PM ET). Visitors can explore these innovations at Agilent booth #512.